



## Navigating Ethical and Legal Dimensions in Artificial Intelligence for Healthcare

Sree Sudha TY<sup>1\*</sup>, Hemasri Velmurugan<sup>2</sup> and KSBS Krishna Sasanka<sup>3</sup>

<sup>1</sup>Assistant Professor, Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Deoghar, Jharkhand, India

<sup>2</sup>Junior Resident, Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

<sup>3</sup>Associate Professor, Department of ENT, All India Institute of Medical Sciences (AIIMS), Deoghar, Jharkhand, India

**\*Corresponding Author:** Sree Sudha TY, Assistant Professor, Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Deoghar, Jharkhand, India.

**DOI:** 10.31080/ASPS.2024.08.1071

**Received:** April 22, 2024

**Published:** May 21, 2024

© All rights are reserved by **Sree Sudha TY, et al.**

### Abstract

Health care Artificial Intelligence (HCAI) is readily being used in a broad range of sectors, including medicine, and is commonly thought of as a strategy that may replace human experts in basic medical services. HCAI, on the other hand, poses a number of problems and ethical considerations. This review analyses and discusses HCAI, including the use and potential of HCAI, particular ethical challenges relevant to HCAI, and recommended sustainable governance approaches. Although HCAI's enormous promise has been realised, the ethical difficulties posed by its implementation have introduced novel regulatory needs. To assure reliable HCAI, the establishment of an ethical global governance structure and framework, as well as unique standards for AI use in medicine, is recommended.

**Keywords:** Artificial Intelligence; Computer; Ethics; Challenges; Health Care System

### Introduction

In the last six years, a slew of Health care Artificial Intelligence (HCAI) ethical frameworks have emerged in response to the growing issues posed by HCAI deployment in a variety of areas, including healthcare. Although there is a lasting culture of medical ethics in healthcare systems, HCAI applications are testing the ethical and regulatory frameworks that are currently in place [1]. While some of these technologies have the ability to improve the patient experience, ethicists have warned that HCAI has the capacity to produce or worsen wrongs and harms in the healthcare system and have been demonstrated to generate skewed results [2]. It is essential that HCAI upholds the principles that people cherish [3]. This review looks into how artificial intelligence has implemented ethics frameworks, how these implementations have been examined, and if they have been effective. HCAI specific ethi-

cal frameworks in healthcare are neglected and are usually used in conjunction with conventional ethical frameworks [4]. The operationalization of ethical frameworks is a complex endeavour fraught with difficulties at several levels, including ethics principles, design, technological, organisational, and regulatory issues. It is essential that AI ethics mirror human ideals, although it is yet unclear how this could be accomplished [5]. Despite the fact that multidisciplinary techniques provide assurance, how an ethics framework is used in an HCAI is rarely revealed, and transparency is necessary for trustworthy HCAI.

### Subfields of HCAI

AI is increasingly being employed not just in disease diagnosis, but also in disease management and prediction analysis.

The following are the four subfields of AI in healthcare:

- **Machine learning (ML):** It is a statistical approach-based programming technique that allows a computer system to learn and recognise patterns to model without explicit instructions.
- **Natural Language Processing (NLP):** A computer's capacity to understand spoken and written language is demonstrated through it.
- **Artificial neural networks (ANNs) and deep learning (DL):** The ANN is made up of discrete components that act as synthetic neurons that have been designed to carry out computer tasks and recognise intricate patterns. DL needs huge datasets for training multi-layered neural networks.
- **Computer Vision:** Visual search, trend analysis, augmented reality, and virtual reality are all components of it [6,7].

#### Applications and ethics in data management

The main advantage of health care AI (HCAI)-based research is the utilisation of data produced for electronic health records. If the primary data and information technological platforms fail to stop the dispersion of diverse or poor-quality data, such data may be challenging to use. However, HCAI in records may be utilised for educational purposes, quality enhancement, and health service optimisation. Before going through the traditional road for academic publication, standard structure, and medical assistance tools, HCAI that is properly constructed and taught with adequate data can assist in finding clinical best practises from electronic health information. HCAI may also help design new clinical practise modes of healthcare delivery by analysing clinical practise patterns obtained from e-health data. The disadvantages, including the potential for accuracy issues and data breaches, are highlighted by the deployment of HCAI. The usage of electronic medical records may be utilised to enhance clinical treatment, conduct scientific research, and optimise patient care; nevertheless, there is a chance that data will be shared or compromised and used for improper purposes. Other ethical questions include who owns an individual's healthcare data and patient history, when and with whom this information will be shared, and if consent is required [1,8,9].

#### Applications and ethics in drug development

HCAI is anticipated to streamline and expedite medication development in the coming years. The discovery of drugs, which is

now carried out by humans and requires a lot of effort, can be handled by HCAI. It can also leverage data processing to use robots and projections to analyse genetic targets, organs, medications, illness, and disease development. The possibilities for how HCAI may assist patients in their recuperation appear to be nearly limitless. But there is a continuous debate over HCAI and whether a new set of regulations is required or whether the present rules are sufficient to safeguard people from the potential downsides of HCAI. The application of artificial intelligence in healthcare has enormous promise, but it also raises ethical concerns that must be addressed. These main factors are as follows: permission to use data after receiving informed permission; security and openness; the fairness and biases of algorithms; and data security. Legislators must take proactive steps to address these ethical concerns so that the benefits of HCAI exceed the risks [1,8,9].

#### Ethical challenges

There is endless discussion about whether AI falls within already-existing legal categories or if a new category with its own characteristics and ramifications should be created. Although the application of AI in clinical settings has enormous promise for improving healthcare, it also presents ethical considerations that must now be addressed. A pivotal discussion in India revolves around the formulation of extensive ethical and legal structures specifically tailored to tackle the distinctive hurdles presented by AI in healthcare systems. It is imperative to guarantee that AI algorithms and models align with ethical principles, steer clear of biases, and uphold patient autonomy. Moreover, an ongoing discourse centres on the identification of liability and accountability in instances of errors or adverse outcomes, demanding a resolution [10,11].

#### Bias in HCAI

The fairness of AI systems is intricately tied to the impartiality of their training data, a particularly pertinent issue in healthcare datasets susceptible to historical biases. Failing to address these biases adequately can perpetuate and exacerbate inequalities in healthcare delivery. Take, for instance, an AI algorithm trained predominantly on a dataset from a specific demographic; when applied to other populations, the model may reflect biases ingrained in its training data. The role of AI in modern technology is shifting from a desirable component to an essential one. Studies suggest that AI systems can incorporate and propagate social and human biases on a significant scale. While the methodology itself shouldn't

shoulder blame, responsibility lies with the underlying data. It is feasible to train models using data containing human assessments or reflecting the second-order effects of social or cultural injustices. Practices related to data collection and usage have the potential to introduce bias, with user-supplied data acting as a potential feedback loop [6,12].

### Expert opinion

Another focal point of discussion is the approval and integration of AI healthcare systems by both physicians and patients. Issues such as worries about the potential displacement of healthcare professionals, the influence on the doctor-patient rapport, and the capability of AI systems to deliver precise and trustworthy diagnoses and treatments are key aspects that require resolution. There may be a shortage of practical ways or frameworks to test for adherence to sustaining ethical values across the life cycle of HCAI; additional research to develop such practical tools is required. Furthermore, further study is needed to identify diverse stakeholders, users, and beneficiaries of HCAI and involve them in a conversation about AI ethics and practical ways to safeguard IT. For ethical AI to be ensured there has to be multidisciplinary coordination between regulatory, legislative authorities, and other stakeholders. In order to address the issues of equality and diversity, it is also necessary to give proper thought to the consequences for public health and global health [13,14].

### Transparency and clarity

AI models employed in healthcare often function as “black boxes,” wherein the decision-making process isn’t readily understandable or explainable to humans. This lack of transparency gives rise to ethical and legal dilemmas, as patients and healthcare providers may hesitate to trust or embrace AI-driven diagnoses or treatment suggestions without comprehending the underlying reasoning.

To tackle this issue, endeavours should be undertaken to design AI models that are transparent and explainable. This involves creating interpretable algorithms and offering clear insights into the factors influencing AI-generated outcomes. Enhanced transparency not only nurtures trust but also empowers healthcare providers to make informed decisions and encourages patients to actively engage in their own care.

### Conclusion

Algorithms created by AI are being utilised more often to improve patient outcomes and surgical outcomes, often outperforming people. The healthcare era of artificial intelligence is likely to be modest, coexist with current systems, or replace them, and delaying adoption is probably unethical and unscientific. By addressing the ethics of emerging HCAI technologies and advancements, those aiming to use HCAI ethically and legally may get insightful information. Key considerations demanding attention include privacy and data security, bias and discrimination, transparency and explainability, liability and accountability, informed consent, regulatory frameworks, and equitable access. This review focuses on how ethical issues about HCAI are addressed in literature, with the purpose of examining how opinions on HCAI ethics have been addressed in research. This has the potential to contribute to the development of HCAI deployment methodologies and policies that take into consideration different perspectives.

### Consent for Publication

Not applicable.

### Financial Support

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### Conflict of Interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Acknowledgements

Declared none.

### Bibliography

1. Seriana I., *et al.* “Phytochemicals characterizations OF neem (*Azadirachta indica* A. Juss) leaves ethanolic extract: an important medicinal plant as male contraceptive candidate”. *Rasayan Journal of Chemistry* 14.1 (2021): 343-350.
2. Rahmani A., *et al.* “Pharmacological and therapeutic potential of neem (*Azadirachta indica*)”. *Pharmacognosy Reviews* 12.24 (2018): 250-255.

3. Uzzaman S. "Pharmacological activities of neem (*Azadirachta indica*): A review". *International Journal of Pharmacognosy and Life Science* 1 (2020): 38-41.
4. Alzohairy MA. "Therapeutics role of *Azadirachta indica* (Neem) and their active constituents in diseases prevention and treatment". *Evidence-Based Complementary and Alternative Medicine* (2016).
5. Seriana I, *et al.* "Phytochemicals characterizations OF neem (*Azadirachta indica* A. Juss) leaves ethanolic extract: an important medicinal plant as male contraceptive candidate". *Rasayan Journal of Chemistry* 14.1 (2021): 343-350.
6. Herrera-Calderon O., *et al.* "*Azadirachta indica*: Antibacterial activity of neem against different strains of bacteria and their active constituents as preventive in various diseases". *Pharmacognosy Journal* 11.6s (2021).
7. Lisanti E., *et al.* "The DNA and spermatozoa quality of mice (*Mus musculus albinus*) after administration aqueous leaves and seeds extract of neem (*Azadirachta indica* A. Juss)". *Journal of Pharmacy* 6.10 (2016): 1-9.
8. Daniyal M and Akram M. "Antifertility activity of medicinal plants". *Journal of the Chinese Medical Association* 78.7 (2015): 382-388.
9. Aigbiremolen AA and Odigie MO. "Modulations of neem leaf extract on reproductive hormones of male wistar rats". *Journal of Bioengineering and Biomedical Science* 8.2 (2018): 1-4.
10. Uzzaman S. "Pharmacological activities of neem (*Azadirachta indica*): A review". *International Journal of Pharmacognosy and Life Science* 1 (2020): 38-41.
11. Jattan SS, *et al.* "Perspectives in intensive management of neem plantations" (2021).
12. Natarajan V, *et al.* "Effect of *Azadirachta indica* (neem) on the growth pattern of dermatophytes". *Indian Journal of Medical Microbiology* 21.2 (2003): 98-101.
13. Saddiqe Z and Maimoona A. "Phytochemical analysis and anthelmintic activity of extracts of aerial parts of *Solanum nigrum* L". *Biologia* (2021).
14. Kumar HK, *et al.* "Evaluation of anthelmintic activity of *Bambusa arundinacea*". *Asian Journal of Pharmacy and Technology* 2.2 (2012): 62-63.
15. Harborne JB. "The biochemical systematics of flavonoids". In *The flavonoids* (1975): 1056-1095.
16. Shivkar YM and Kumar VL. "Anthelmintic activity of latex of *Calotropis procera*". *Pharmaceutical Biology* 41.4 (2003): 263-265.
17. Martin RJ. "Modes of action of anthelmintic drugs". *The Veterinary Journal* 154.1 (1997): 11-34.